Seletalisib

Drug Profile

Seletalisib

Alternative Names: UCB-5857

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator UCB
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Immunomodulators; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Immunodeficiency disorders
  • Phase II Sjogren's syndrome
  • Phase I Plaque psoriasis

Most Recent Events

  • 08 Jun 2016 Phase-III clinical trials in Immunodeficiency disorders (In adolescents, In adults) in Spain (PO) (EudraCT2015-005541-30)
  • 21 Dec 2015 Phase-I clinical trials in Immunodeficiency disorders (Activated PI3K delta syndrome) (In adolescents, In adults) in Germany (PO) (EudraCT2015-002900-10)
  • 01 Feb 2015 UCB Pharma completes a phase I trial for Healthy volunteers in United Kingdom (NCT02207595)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top